KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $611000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 8.26% to $611000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, down 0.66% year-over-year, with the annual reading at $2.5 million for FY2025, 0.66% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $611000.0 at Xenon Pharmaceuticals, down from $641000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.7 million in Q3 2023, with the low at -$629000.0 in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $473750.0, with a median of $481000.0 recorded in 2022.
  • Peak annual rise in Depreciation & Amortization (CF) hit 384.36% in 2023, while the deepest fall reached 312.5% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $270000.0 in 2021, then grew by 9.63% to $296000.0 in 2022, then plummeted by 312.5% to -$629000.0 in 2023, then soared by 205.88% to $666000.0 in 2024, then fell by 8.26% to $611000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $611000.0, $641000.0, and $632000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.